Physician profile
Mark L Fehr
NPI 1275781338
$4,435.84
in general payments reported to CMS, 2019-2025
40 companies · $887 in 2025
The $887 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2020: $119 · 2021: $31.82 · 2022: $581 · 2023: $1,006 · 2024: $1,178 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,023 · Education: $49.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,022.73 |
| Education | $49.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,107.00 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $366.96 | 2019-2025 | |
| Ucb, INC. | $341.45 | 2019-2025 | Briviact, Zilbrysq, Nayzilam |
| Sk Life Science, INC. | $271.05 | 2022-2025 | |
| Lilly USA, LLC | $218.57 | 2020-2024 | Emgality, Kisunla, Amyvid |
| Pfizer INC. | $214.89 | 2023-2025 | |
| Neurelis, INC. | $198.03 | 2023-2025 | Valtoco |
| Amgen INC. | $179.48 | 2019-2025 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $152.44 | 2019-2025 | Austedo Xr |
| Eisai INC. | $146.16 | 2022-2024 | |
| Lundbeck LLC | $115.20 | 2023-2024 | Vyepti |
| Supernus Pharmaceuticals, INC. | $88.23 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $87.37 | 2024-2025 | Ingrezza |
| Csl Behring | $80.70 | 2019-2023 | Hizentra |
| Argenx US, INC. | $69.70 | 2022-2023 | Vyvgart |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Fehr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.